WPRIM Management System> DCMS> Journal of Clinical Hepatology> 2023> 39> 7

Volume: 39 Issue: 7

1. Clinical application of early transjugular intrahepatic portosystemic shunt and related and research advances Page:1513—1522
2. Effect of systemic therapeutic drugs for hepatocellular carcinoma on portal hypertension Page:1523—1528
3. Comparison of endoscopic therapy and TIPS in prophylaxis and treatment of variceal bleeding in decompensated portal hypertension Page:1529—1534
4. ｜The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis Page:1534—1534
5. Current status and advances in transjugular intrahepatic portosystemic shunt in treatment of refractory ascites due to portal hypertension Page:1535—1540
6. Association between transjugular intrahepatic portosystemic shunt and sarcopenia in patients with liver cirrhosis Page:1541—1546
7. Guidelines for the integrated traditional Chinese and Western medicine diagnosis and treatment of acute-on-chronic liver failure Page:1547—1552
8. Interpretation of guidelines for the prevention and treatment of chronic hepatitis B (2022 edition) Page:1553—1559
9. Interpretation of guideline for the prevention and treatment of hepatitis C (2022 version): Antiviral therapy for special populations Page:1560—1563
10. Value of blood lipid parameters in predicting the progression of HBV-related acute-on-chronic pre-liver failure Page:1564—1569
11. Clinical features of idiopathic non-cirrhotic portal hypertension: An analysis of 74 patients Page:1570—1577
12. Value of serum chitinase-3-like protein 1 in predicting the risk of decompensation events in patients with liver cirrhosis Page:1578—1585
13. Current reviewers Page:1585—1585
14. Risk factors for pulmonary infection after laparoscopic surgery in treatment of hepatocellular carcinoma with liver cirrhosis and portal hypertension Page:1586—1591
15. Efficacy of hepatic arterial infusion chemotherapy and its multimodality therapeutic regimens in treatment of patients with advanced hepatocellular carcinoma and related prognostic factors Page:1592—1599
16. Value of the nomogram based on HALP score in predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy Page:1600—1608
17. Efficacy and safety of microwave ablation combined with systemic chemotherapy in treatment of recurrent intrahepatic cholangiocarcinoma Page:1609—1616
18. Ursolic acid in Page:1617—1626
19. Analysis of influencing factors on biliary complications after orthotopic liver transplantation Page:1627—1632
20. Effect of early thoracic paracentesis drainage on acute lung injury in severe acute pancreatitis Page:1633—1642
21. Influencing factors for acute necrotizing pancreatitis in Eastern and Western countries: A meta-analysis Page:1643—1656
22. Value of serum interleukin-6 and tumor necrosis factor-α in early diagnosis of severe acute pancreatitis Page:1657—1664
23. Clinical and pathological features of drug-induced liver injury with different types of bile duct injury: An analysis of four cases Page:1665—1672
24. Liver transplantation for treating refractory hepatic inflammatory myofibroblastic tumor: A case report Page:1673—1677
25. Primary atypical epithelioid hemangioendothelioma of the neck of the gallbladder: A case report Page:1678—1680
26. Mechanism of action of lipotoxicity in nonalcoholic steatohepatitis Page:1681—1686
27. ｜Intracellular labile iron is a key regulator of hepcidin expression and iron metabolism Page:1686—1686
28. Research advances in ferroptosis in the pathogenesis and treatment of nonalcoholic fatty liver disease Page:1687—1695
29. Research advances in the role of Page:1696—1702
30. Effectiveness of increasing alcohol excise taxes in the management of alcohol-associated liver disease in China Page:1703—1707
31. Role of the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway in alcoholic liver disease Page:1708—1713
32. The mechanism of action of partial splenic artery embolization in treatment of liver cirrhosis and hypersplenism Page:1714—1720
33. Research advances in rivaroxaban in the treatment of portal vein thrombosis in liver cirrhosis Page:1721—1727
34. Research advances in brain lactate level and hepatic encephalopathy Page:1728—1733
35. Role of lipopolysaccharide in the development and progression of liver cancer Page:1734—1739
36. Research advances in transcatheter arterial chemoembolization combined with targeted agents or anti-PD-1/PD-L1 monoclonal antibody in treatment of patients with unresectable hepatocellular carcinoma Page:1740—1746
37. Role and potential significance of peroxisome proliferator-activated receptors in liver diseases Page:1747—1753
38. Research advances in animal models of cholestatic liver disease Page:1754—1760

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.